houston innovators podcast episode 57

New Houston life science incubator leader is focusing on inclusion in health innovation

Fiona Mack has joined JLABS @ TMC as head of the incubator. She shares her vision for the lab on this week's episode of the Houston Innovators Podcast. Photo courtesy of JLABS

By now, Fiona Mack has worked in a few sectors and stages of health innovation — mostly within oncology and biopharmaceuticals. However, since being named the head of JLABS @ TMC a few months ago, she's jumped headfirst into Houston life science startup incubation.

"I've been kind of drinking from the fire hose. I've really tried to understand the J&J organization, which is quite global in its scope across multiple sector areas," Mack shares on this week's episode of the Houston Innovators Podcast. "On a regional level, I've been focusing on understanding my portfolio."

On her plate right now is assessing the needs of the incubator's 49 member companies in the portfolio. Additionally, she's working on recognizing any gaps in leadership — the position has been vacant around a year and a half since the former head, Tom Luby, transitioned to leading the TMC Innovation Institute — and understanding the needs of the Texas innovation ecosystem.

"As I learn more about the history of life science sector in Texas, over the past 20 years there has been an impetuous to build up this critical mass of companies here to really make it a strong hub that competes with the energy sector to make it a pillar of the economy here," Mack says.

One of the things that's top of mind for Mack is a focus on diversity — both from an entrepreneurship and a representation standpoint.

"From a research perspective, there's a strong effect of having a lack of diversity in a lot of the metrics we're looking at," she shares.

Mack says innovation is driven by data, and data, especially when your using that information to treat a diverse group of people, needs to be representative. And Houston is a great place to make that happen.

"What information are we putting into those datasets? If it only represents a homogenous population, it certainly can't be applied to the real world," Mack says. "There's a need to be much more inclusive into what we're analyzing. Houston, in terms of its population, is highly diverse — and we can speak about it ethnically and from an economic standpoint."

Mack shares more of her big picture vision for JLABS @ TMC on the episode, as well as what her early impressions of Houston have been so far. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News